Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) on Wednesday.
What Happened
Harmony's offer to acquire all outstanding shares of Zynerba for $60 million or $1.1059 per share in cash, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million or approximately $2.5444 in additional cash per share, subject to the achievement of specific clinical, regulatory and sales milestones expired at 5:00 p.m. ET time on Tuesday, October 10, 2023.
Following the acceptance of the tendered shares, Harmony completed the acquisition ...